Advisors Capital Management LLC Purchases 630 Shares of Eli Lilly and Company $LLY

Advisors Capital Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,551 shares of the company’s stock after purchasing an additional 630 shares during the period. Advisors Capital Management LLC’s holdings in Eli Lilly and Company were worth $8,051,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock worth $61,771,785,000 after purchasing an additional 551,659 shares during the period. Laurel Wealth Advisors LLC raised its stake in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Norges Bank acquired a new position in Eli Lilly and Company in the second quarter valued at $8,827,714,000. Jennison Associates LLC boosted its position in Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after acquiring an additional 226,620 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Eli Lilly and Company by 2.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after acquiring an additional 103,119 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on LLY. Morgan Stanley raised their target price on Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. Argus raised their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. National Bank Financial set a $1,286.00 price objective on shares of Eli Lilly and Company in a report on Monday, December 1st. Finally, Daiwa Securities Group raised their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,219.68.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,021.53 on Thursday. The company has a fifty day moving average price of $1,054.92 and a 200-day moving average price of $913.16. The firm has a market cap of $963.67 billion, a price-to-earnings ratio of 44.51, a PEG ratio of 1.21 and a beta of 0.39. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 30.15%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CSL signed an exclusive licensing deal for Lilly’s clazakizumab (upfront and milestone potential ~$100M), giving Lilly a partner to commercialize an antibody targeting heart events in end‑stage kidney disease — expands near‑term partner-funded optionality and de‑risks development costs. Eli Lilly Enters $100 Million Licensing Agreement with CSL Limited for Clazakizumab
• Positive Sentiment: Medicare expansion for GLP‑1 weight‑loss coverage appears to be easing pricing and access concerns, which supports longer-term demand and reduces downside to peak pricing assumptions for drugs like Zepbound and tirzepatide. Eli Lilly Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns
• Positive Sentiment: Daiwa raised its price target to $1,250 and kept a buy rating — a sentiment vote from analysts that can support upward momentum and attract flows from model/coverage-driven funds. Daiwa Securities Adjusts Price Target on Eli Lilly
• Positive Sentiment: Phase 3b data show Lilly’s Taltz (ixekizumab) + Zepbound (tirzepatide) produced superior efficacy in adults with relevant indication — positive clinical readout that could broaden label use and commercial synergies. Taltz and Zepbound Phase 3b Results
• Positive Sentiment: Retevmo showed improved event‑free survival in an adjuvant early‑stage lung cancer trial — expands oncology franchise and supports durable revenue diversification beyond GLP‑1s. Lilly’s Retevmo Looks to Broaden Reach with Adjuvant Trial Win
• Positive Sentiment: Lilly plans a $1B investment to build India capability as a global export/manufacturing hub — supports cost-effective scale for blockbuster drugs and supply resilience. Lilly Targets India as Global Export Hub
• Neutral Sentiment: Lilly reportedly stocked ~$1.5B of orforglipron pills ahead of an expected FDA decision — shows supply readiness but ties up capital and raises near‑term inventory/cost risk depending on uptake. Company Loads Up $1.5B of Weight-Loss Pills
• Neutral Sentiment: Brand/marketing move: Shaquille O’Neal named an ambassador for a Team USA recovery program in partnership with Lilly — modest PR/brand impact rather than a material revenue driver. Shaquille O’Neal Named Ambassador
• Negative Sentiment: Competition risk: analysts and industry pieces highlight intense GLP‑1 competition (Novo Nordisk’s momentum and new oral entrants). Sustaining pricing and share amid multiple launches remains a material long‑term risk. Can LLY’s Next-Gen Obesity Pipeline Sustain Growth?

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.